English

YEAR-END REPORT 2012 CHRONTECH PHARMA AB

Report this content

  • Research and development costs amounted to SEK 13.9 (15.2) m
  • The loss after tax was SEK -19.7 (-20.2) m
  • Earnings per share were SEK -0.11 (-0.17)
  • The company had no net sales for the period
  • The results from the controlled phase II clinical study of ChronVac-C® in combination with standard-of-care will be obtained and reported during Q1 2013
  • The development of ChronTechs IVIN technology show promising results in small and large animals
  • The Board is working to solve the company’s financing
  • Opsonic Therapeutics, a company partly owned and co-founded by ChronTech, has received an initial investment of 750 000 USD for the development of ChronTechs RAS technology

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

Documents & Links